An anti-HER2 antibody–drug conjugate (RC48-ADC) that binds HER2 on tumor cells, is internalized, and releases the microtubule inhibitor MMAE to disrupt tubulin and induce cell-cycle arrest/apoptosis; Fc functions may add ADCC against HER2-positive cells.
Humanized anti‑HER2 IgG1 antibody linked to the microtubule inhibitor MMAE. After binding HER2 on tumor cells, the ADC is internalized and releases MMAE to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; Fc-mediated effector functions may add ADCC against HER2-expressing cells.
ADC binds HER2 on tumor cells, is internalized, and releases MMAE intracellularly to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; Fc effector functions may add ADCC against HER2-expressing cells.
Fc-engineered anti-CD19 IgG1 monoclonal antibody that targets CD19 on malignant B cells and induces ADCC/ADCP and direct apoptosis.
Fc-engineered humanized anti-CD19 IgG1 monoclonal antibody that binds CD19 on B cells; enhanced Fc-gamma receptor binding drives antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and it can induce direct apoptosis, depleting CD19-positive malignant B cells.
Binds CD19 on B cells; the Fc region engages Fc-gamma receptors on NK cells/macrophages to mediate ADCC/ADCP and can also trigger direct apoptosis of CD19+ cells.
Monoclonal antibodies linked to cytotoxic payloads that deliver targeted chemotherapy to B-cell antigens.
Monoclonal antibody targets B‑cell surface antigens and, after binding and internalization, releases a linked cytotoxic payload that damages DNA or disrupts microtubules to induce apoptosis; Fc-mediated effector functions may also contribute to tumor cell killing.
ADC binds CD19 on B cells, is internalized, and releases a cytotoxic payload that damages DNA or microtubules to induce apoptosis; Fc-mediated ADCC/CDC may also contribute.
Monoclonal antibodies linked to cytotoxic payloads that deliver targeted chemotherapy to B-cell antigens.
Monoclonal antibody targets B‑cell surface antigens and, after binding and internalization, releases a linked cytotoxic payload that damages DNA or disrupts microtubules to induce apoptosis; Fc-mediated effector functions may also contribute to tumor cell killing.
An ADC binds CD79b on B cells, is internalized, and releases a cytotoxic payload that disrupts microtubules or damages DNA to induce apoptosis; Fc-mediated ADCC/CDC may also contribute.
Anti-CD20 monoclonal antibody that depletes CD20-positive B cells to reduce ANCA (PR3/MPO) autoantibody production.
Anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B cells and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing ANCA (PR3/MPO) autoantibody production.
Rituximab binds CD20 on B cells and eliminates them via complement-dependent cytotoxicity and Fc-mediated ADCC by immune effector cells; CD20 crosslinking can also induce apoptosis.